Featured Research

from universities, journals, and other organizations

Researchers validate molecular signature to predict radiation therapy benefit

Date:
August 16, 2012
Source:
H. Lee Moffitt Cancer Center & Research Institute
Summary:
Researchers have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

The results appeared in a recent issue of Clinical Cancer Research, a publication of the American Association for Cancer Research.

The study examined patients with breast cancer who had been treated with radiation therapy and demonstrated that a radiosensitivity molecular signature (RSI) could predict clinical outcomes exclusively in patients treated with radiation therapy. The radiosensitivity molecular signature (RSI) used by the research team had previously been tested and validated for rectal, esophageal, and head and neck cancers. The technology, which identifies radiosensitivity and radioresistance, opens the door to biologically guided radiation therapy and offers the potential for better outcomes.

"Developing a radiosensitivity predictive assay has been a goal of radiation biology for decades," said Javier F. Torres-Roca, M.D., member of the Experimental Therapeutics program at Moffitt. "This effort supports the emphasis on personalized medicine, where the goal is to use molecular signatures to guide therapeutic decisions."

According to Torres-Roca, approximately 60 percent of all cancer patients receive radiation therapy during their treatment. Yet until now, no molecular diagnostic or biomarker of radiosensitivity had been developed to predict its benefit.

The radiosensitivity molecular signature was developed based on gene expression for 10 specific genes and a linear regression algorithm. RSI was developed in 48 cancer cell lines using a systems-biology strategy focused on identifying biomarkers for cellular radiosensitivity.

This study validated RSI's benefit when researchers found that radiosensitive breast cancer patients had an improved five-year, relapse-free survival when compared to radioresistant patients.

"This study validated RSI in 503 patients in two independent data sets," Torres-Roca said. "We have validated RSI in five independent cohorts totaling 621 patients, so this latest validation study, to the best of our knowledge, makes this technology the most extensively validated molecular signature in radiation oncology."

The successful transition from applying the technology to cell lines to patient application also suggests that the biological basis of cellular radiosensitivity is conserved between cell lines and patients and also across epithelial tumors, Torres-Roca said.

"We propose that RSI is a predictive biomarker of radiation therapy therapeutic benefit for patients with breast cancer," Torres-Roca said. "This novel biomarker provides an opportunity to integrate individual tumor biology with clinical decision-making in radiation oncology."

Torres-Roca's research was supported in part by the National Cancer Institute, part of the National Institutes of Health, through the grant number R21 CA101355 and R21 CA135620; the National Functional Genomics Center; and the State of Florida Bankhead-Coley Foundation (09BB-22).

The RSI technology is owned by Moffitt and licensed to Cvergenx, Inc., an advanced cancer molecular diagnostics company committed to delivering personalized radiation therapy to cancer patients.


Story Source:

The above story is based on materials provided by H. Lee Moffitt Cancer Center & Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Eschrich, W. J. Fulp, Y. Pawitan, J. A. Foekens, M. Smid, J. W. M. Martens, M. Echevarria, V. Kamath, J.-H. Lee, E. E. Harris, J. Bergh, J. F. Torres-Roca. Validation of a Radiosensitivity Molecular Signature in Breast Cancer. Clinical Cancer Research, 2012; DOI: 10.1158/1078-0432.CCR-12-0891

Cite This Page:

H. Lee Moffitt Cancer Center & Research Institute. "Researchers validate molecular signature to predict radiation therapy benefit." ScienceDaily. ScienceDaily, 16 August 2012. <www.sciencedaily.com/releases/2012/08/120816075444.htm>.
H. Lee Moffitt Cancer Center & Research Institute. (2012, August 16). Researchers validate molecular signature to predict radiation therapy benefit. ScienceDaily. Retrieved April 16, 2014 from www.sciencedaily.com/releases/2012/08/120816075444.htm
H. Lee Moffitt Cancer Center & Research Institute. "Researchers validate molecular signature to predict radiation therapy benefit." ScienceDaily. www.sciencedaily.com/releases/2012/08/120816075444.htm (accessed April 16, 2014).

Share This



More Health & Medicine News

Wednesday, April 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Even Casual Marijuana Use Alter Your Brain?

Could Even Casual Marijuana Use Alter Your Brain?

Newsy (Apr. 16, 2014) A new study conducted by researchers at Northwestern and Harvard suggests even casual marijuana use can alter your brain. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Now Linked To 121 Deaths

Ebola Outbreak Now Linked To 121 Deaths

Newsy (Apr. 15, 2014) The ebola virus outbreak in West Africa is now linked to 121 deaths. Health officials fear the virus will continue to spread in urban areas. Video provided by Newsy
Powered by NewsLook.com
Cognitive Function: Is It All Downhill From Age 24?

Cognitive Function: Is It All Downhill From Age 24?

Newsy (Apr. 15, 2014) A new study out of Canada says cognitive motor performance begins deteriorating around age 24. Video provided by Newsy
Powered by NewsLook.com
How Mt. Everest Helped Scientists Research Diabetes

How Mt. Everest Helped Scientists Research Diabetes

Newsy (Apr. 15, 2014) British researchers were able to use Mount Everest's low altitudes to study insulin resistance. They hope to find ways to treat diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins